Breakthrough Drugs Target Smoking and Obesity in Ortho Care

Subscribe today to listen to this content Get Access

Tackling Two Orthopedic Risk Factors: Smoking and Obesity

Two investigational drugs are progressing through the regulatory pipeline with notable promise, aiming to address two of the most persistent and impactful comorbidities in orthopedic medicine: smoking and obesity. These conditions are frequently associated with increased perioperative risks, delayed healing, and suboptimal surgical outcomes.

Early data is good enough to move these two drugs—cytisinicline and ASC-30—along the regulatory pathway. Of course, it’s difficult to predict when they will emerge for commercial use, but they are very interesting and have promise.